– Preclinical data demonstrating OQL051, a gut-restricted CDK4/6 inhibitor, as a potential prophylactic treatment for chemotherapy-induced diarrhea – Survey of academic and community oncologists studying the prevention and treatment patterns of papulopustular, acneiform skin toxicity associated with epidermal growth factor receptor inhibitor (EGFRi) therapy, demonstrating that the majority (98%) of doctors would use a novel agent to treat this adverse event if available SEATTLE, May 27, 2022 /PRNewswire/ — OnQuality Pharmaceuticals (“OnQuality”), a targeted oncology supportive therapy...